JérémieNoel

Associate

Paris + 33.1.56.59.38.94

Jérémie Noel's practice areas include venture capital, private equity, M&A, and capital markets.

He regularly represents issuers (e.g., Ivalua, Kalray, Less, Lifen, MirSense, and Shippeo) and investors (Alven Capital Partners, Andera Partners, Elaia Partners, Hi Inov, Idinvest Partners, and Wellington Partners) in venture capital deals and assists public and private emerging companies on a broad range of corporate and commercial matters in connection with their business and projects.

Illustrative transactions in which Jérémie has advised include the share capital increases of Ivalua, Lendix, Less, MirSense, and TRiCares; the acquisition of Availpro by AccorHotel; and the IPO of Kalray.

Experience

  • Shippeo receives investment by Bpifrance, Partech Partners, ETF Partners, and NBT CapitalJones Day advised Shippeo SAS, a French company that develops a collaborative platform for road transportation management, in connection with its €20 million investment by Bpifrance, Partech Partners, ETF Partners, and NBT Capital.
  • Alven, Fa Dièse and other main shareholders sell SoCloz to SavoyeJones Day advised Alven, Fa Dièse and other main shareholders in connection with the sale of SoCloz, a French company specialized in the development and marketing of SAAS software that allows retailers to digitize their points of sale and manage their omnicanality, to Savoye.
  • Swile raises €70 million in financing roundJones Day advised Swile, a French company providing digital meal vouchers and other non-food benefits (reimbursements, gift cards, and events) to employees via a prepaid card and app, in connection with its €70 million round of financing led by Index Ventures, Bpifrance Participations, and Idinvest Partners.
  • PureTerra Ventures participates in €7 million financing round of Rubix SIJones Day represented PureTerra Ventures Ltd in connection with the €7 million round of financing of Rubix SI, a company that develops and sells connected objects and solutions to monitor interior and exterior nuisances.
  • Medicxi Ventures participates in €18.5 million financing round of Alderaan BiotechnologyJones Day advised Medicxi Ventures in connection with the €18.5 million financing round of Alderaan Biotechnology, a company engaged in the research and development of antibodies targeting certain molecules for the treatment of cancer.
  • ChapsVision acquires Compario (Sparkow)Jones Day advised ChapsVision S.A.S., a software company, in connection with the acquisition of Compario (Sparkow), a French company active in the publishing of expert merchandising SaaS solutions.
  • Welcome to the Jungle raises €20 million in financing roundJones Day represented Welcome to the Jungle, a developer and operator of a recruitment and employer branding solution, in connection with the €20 million (US$22.3 million) round of financing led by Gaia Capital Partners alongside historical shareholders, Bpifrance, XAnge, and SGPA (Jean-Paul Guisset).
  • Mathym sold to BaikowskiJones Day advised the selling shareholders of Mathym, a French company operating in the area of nanomaterials and specializing in the development, manufacturing, and commercialization of nanodispersions, in its sale to Baikowski, a French manufacturer of specialist industrial minerals.
  • Inotrem raises €39 million in Series B financing roundJones Day advised Inotrem S.A., a French biotech company specialized in immunotherapy for acute and chronic inflammatory syndromes, in connection with its €39 million (US$43 million) Series B round of financing led by Morningside Ventures and joined by Invus as well as historical investors including Andera Partners, Sofinnova Partners, and BiomedInvest.
  • Akeneo raises €41 million in financing roundJones Day advised Akeneo, a French company that develops and sells software for managing data relating to product catalogs as well as its historical investors, Alven Capital Partners and Partech Partners, in connection with Akeneo's €41 million (US$45.1 million) round of financing.
  • Alizé Pharma 3 raises €67 million in financing roundJones Day represented Alizé Pharma 3 SAS, a French company engaged in the research and development of new therapeutic strategies for the treatment of rare endocrine and metabolic diseases, in connection with its €67 million (US$75 million) round of financing led by LSP, and included a syndicate of international investors.
  • Critizr raises €15 million in financing roundJones Day advised Critizr, a French company that develops a customer feedback management solution dedicated to the points of sale, in connection with its €15 million (US$16.8 million) round of financing led by 83North.
  • Incepto Medical raises €5.6 million in financing roundJones Day advised Incepto Medical, a French company engaged in the business of co-creation, development, and distribution of AI-based applications for medical imaging in the field of diagnosis and treatment of diseases, in connection with its €5.6 million (US$6.3 million) round of financing led by AXA Venture Partners, Bpifrance Investissement, and CapDecisif Management.
  • Daphni and Breega Capital participate in €5 million financing round of HemeaJones Day advised Daphni and Breega Capital in connection with the €5 million financing round of Hemea (formerly Travauxlib), a marketplace between homeowners wishing to renovate their houses/apartments and carefully filtered and rated local contractors.
  • Elaia Partners participates in €4.0 million financing round of HeuritechJones Day advised Elaia Partners in connection with the €4.0 million (US$4.4 million) financing round of Heuritech, a French company that develops and operates a product monitoring and trending forecasting solutions for brands and retailers.
  • Endocontrol sold to Canady Life Sciences, Inc.Jones Day advised Endocontrol, a French robotic company, and its main shareholders, Seventure Partners and ACG Management, in connection with its sale in a stock-for-stock transaction to Canady Life Sciences, Inc., a U.S. life sciences company.
  • Elaia Partners and Axeleo Capital participate in €4.0 million financing round of HyperlexJones Day advised Elaia Partners and Axeleo Capital in connection with the €4.0 million (US$4.4 million) financing round of Hyperlex, a French-based company that develops and operates a contract analytics tool and contract management solution for enterprises and legal experts.
  • Elaia Partners participates in €3.0 million financing round of SIM&CUREJones Day advised Elaia Partners in connection with the €3.0 million (US$3.36 million) financing round of SIM&CURE, a French-based developer and operator of simulation software dedicated to neurovascular treatments against aneurysms.
  • Medicxi Ventures participates in €3.3 million investment in Yukin TherapeuticsJones Day represented Medicxi Ventures (UK) LLP in connection with its €3.3 million (US$3.7 million) investment in Yukin Therapeutics, a French-based company engaged in the research and development of small molecules targeting the kinase NIK for the treatment of cancer and inflammatory diseases.
  • JOIN Capital participates in €5.0 million investment in WizzcadJones Day represented JOIN Capital GmbH in connection with its €5.0 million (US$5.7 million) investment in Wizzcad, a French-based company engaged in the design and sale of a specialized software aimed at digitalizing the field operations in the construction, civil works, and industrial sectors.
  • We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.